8-K filing — Bluejay Diagnostics, Inc. (BJDX)
Filed: 2026-11-13 AccNo: 0001213900-26-119686 Size: 276 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Bluejay Diagnostics released baseline data from its SYMON-II study, evaluating the IL-6 biomarker for mortality risk in sepsis patients.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-13 AccNo: 0001213900-26-119686 Size: 276 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Bluejay Diagnostics reported its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical and manufacturing progress for the Symphony platform.
Gainers Co-Diagnostics (NASDAQ:CODX) stock moved upwards by 22.4% to $0.39 during Tuesday's pre-market session. The company's market cap stands at $2.8 million. As per the press release, Q3 earnings came out
Company Achieves Toray Contractual Milestone with Establishment of Manufacturing SiteACTON, MA / ACCESS Newswire / October 13, 2026 / Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"),
SYMON-II Clinical Validation Dataset Represents a Key Milestone as Bluejay Advances the Symphony™ IL-6 Test Toward Regulatory SubmissionACTON, MA / ACCESS Newswire / October 6, 2026 / Bluejay Diagnostics, Inc.